Atossa Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ATOS Nasdaq 2836 www.atossatherapeutics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Atossa Therapeutics, Inc.

Atossa Therapeutics to Present at the Jefferies Global Healthcare Conference - Jun 2nd, 2025 6:45 am
Join Atossa Therapeutics' Exclusive Live Investor Webinar and Q&A Session on May 22 - May 20th, 2025 7:00 am
Are Medical Stocks Lagging Atossa Genetics (ATOS) This Year? - May 15th, 2025 7:40 am
Atossa Therapeutics Announces Full Results from I‑SPY 2 Endocrine‑Optimization Sub‑Study Evaluating Low‑Dose (Z)‑Endoxifen - May 14th, 2025 6:15 am
Atossa Therapeutics Announces First Quarter 2025 Financial Results and Provides a Corporate Update - May 13th, 2025 6:00 am
Atossa Therapeutics and Ainos Interviews Aired on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - May 5th, 2025 7:00 am
Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,281,056, Including 58 Claims Covering Various Formulations for its (Z)-endoxifen Portfolio - Apr 30th, 2025 6:45 am
Atossa Therapeutics Proposes Potentially Groundbreaking Study Aimed at Reducing Interval Breast Cancer in High-Risk Women at AACR 2025 - Apr 29th, 2025 6:45 am
Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,275,684, Further Strengthening (Z)-endoxifen Portfolio - Apr 22nd, 2025 6:45 am
Nona Biosciences and Atossa Therapeutics Partner to Discover Next-Generation Antibody Therapies for Breast Cancer - Apr 10th, 2025 6:00 am
All You Need to Know About Atossa Genetics (ATOS) Rating Upgrade to Buy - Mar 28th, 2025 10:00 am
We Think Atossa Therapeutics (NASDAQ:ATOS) Can Afford To Drive Business Growth - Mar 26th, 2025 6:56 am
Atossa Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update - Mar 25th, 2025 6:00 am
Atossa Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results - Mar 20th, 2025 7:13 am
Atossa Therapeutics Announces Plans to Pursue Metastatic Breast Cancer Indication for (Z)-Endoxifen and Continued Engagement with FDA on Additional Indications - Mar 11th, 2025 6:15 am
Atossa Therapeutics Congratulates Board Director Dr. Tessa Cigler and Weill Cornell Medicine on CDC Grant to Enhance Breast Cancer Care - Feb 5th, 2025 6:00 am
Atossa Therapeutics Responds to PTAB Ruling on U.S. Patent No. 11,572,334 and Announces the Issuance of U.S. Patent No. 12,201,591 - Jan 30th, 2025 6:17 am
Atossa Therapeutics Issues Letter to Shareholders Highlighting 2024 Accomplishments and Outlook for 2025 - Jan 23rd, 2025 6:15 am
Atossa Therapeutics Applauds U.S. Surgeon General’s Advisory Highlighting Alcohol as a Leading Preventable Cause of Breast Cancer - Jan 6th, 2025 7:00 am
Is Atossa Genetics (ATOS) Stock Outpacing Its Medical Peers This Year? - Dec 20th, 2024 7:40 am